Health Care · In Vitro & In Vivo Diagnostic Substances

NEOG NEOGEN CORP SEC Filings & Insider Trading Activity 2026

company
CIK 711377113 filings
Russell 2000

NEOG at a glance

NEOGEN CORP (NEOG, SEC CIK 711377) filed its latest 10-K annual report on July 30, 2026, a 10-Q quarterly report on October 7, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended May 31, 2026 (FY2026), NEOGEN CORP (NEOG) reported revenue of $870.4 million (down 2.7% from FY2025) and a net loss of $7.9 million. Diluted EPS was -$0.04.
  • As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding NEOGEN CORP (NEOG) shares worth $1.2 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Yarwood Jeremy on November 4, 2026 of 9,051 shares at $12.67 per share.
  • In the last 90 days, NEOG insiders reported 1 open-market purchase ($6K) and 1 open-market sale ($115K) on Form 4, a net sale of $109K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2026
$870.4M
−2.7% vs prior year
Insiders · 90 days
1 buy · 1 sell
Net −$109K
13F holders
32 funds
$1.2B · +2 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended May 31, 2026

Full analysis →

Risk Factors

  • Regulatory risk from Australian and New Zealand regulators reviewing $160M Genomics business sale to Zoetis, delaying expected closing beyond H1 FY2027
  • Geopolitical exposure with 51.2% revenue from international markets facing risks including Russia-Ukraine conflict sanctions and Middle East tensions impacting supply and costs
  • Operational risk in ongoing transition of Petrifilm manufacturing from 3M to Neogen with expected completion in FY2027, incurring duplicative costs and regulatory approvals
  • Competitive risk from AI and emerging technologies disrupting animal and food safety markets, requiring effective integration and risk management to maintain competitive position
  • Financial risk from $450M new senior secured term loan and $100M drawn on $250M revolving credit, with covenants restricting investments, dividends, and debt that may limit financial flexibility

Management Discussion & Analysis

  • Revenue $870.4M, down 3% YoY ($24.3M decrease) due to $55.6M discontinued product lines partially offset by $17.3M organic growth
  • Gross margin 46.9% vs 47.1% YoY, slight decline due to volume decreases and duplicative costs; Food Safety operating income $63.4M vs loss $(985.7)M
  • Animal Safety segment revenues $229.3M, down 11% YoY; operating income $24.5M vs $7.3M, best margin improvement; Food Safety segment best revenue performer
  • Operating cash flow $83.2M, up $25.0M; investing cash inflow $70.5M due to $121.7M sale proceeds; financing cash outflow $99.4M driven by debt repayments
  • Management plans growth via innovation, commercial excellence, cost management; sale of Genomics business pending; supply chain and tariff risks to persist in FY2027

Business Overview

  • Core business model: Develop, manufacture, and market food and animal safety diagnostic products, veterinary instruments, pharmaceuticals, and related services worldwide
  • Significant divestiture: Announced agreement to sell Genomics business to Zoetis Inc. for $160 million, pending regulatory approval and closing by mid-fiscal 2027
  • Strategic shift: Divested global Cleaners and Disinfectants business in July 2025, streamlining focus on core Food Safety and Animal Safety segments
  • Employee count: 2,636 total employees globally as of May 31, 2026, with 817 in sales and marketing and 89 in R&D
  • Noteworthy fact: Sales outside the U.S. accounted for 51.2% of total revenues, showing continued international growth and geographic diversification

AI summary of the NEOG 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Aug 31, 2026

Management Discussion & Analysis

  • Revenue $222.8M, up $13.6M or 6.5% YoY
  • Gross margin 47.4% vs 45.4% YoY, operating loss $(1.8)M vs $(16.1)M
  • Food Safety strongest segment: revenue $163.2M, up 7.3%; Animal Safety revenue $59.6M, up 4.4%
  • Cash $172.0M; operating cash flow $12.9M vs $10.8M, with $20.0M term-loan prepayment
  • Headwinds: inflation, tariffs, elevated interest rates, geopolitical tensions; Genomics divestiture reviews expected through December 2026

Risk Factors

  • Genomics divestiture risk: ACCC and NZCC moved reviews to phase two, potentially delaying the $160.0 million Zoetis transaction
  • Product compliance risk: FDA Warning Letter followed contamination findings involving recalled Vet HyCoat units
  • Litigation risk: securities class-action dismissal appealed on September 8, 2026, leaving appeal exposure unresolved
  • Operational risk: Petrifilm internal manufacturing preparation creating duplicative costs and production inefficiencies
  • Debt liquidity risk: $774.2 million net debt outstanding, with $199.9 million revolving borrowing capacity available

AI summary of the NEOG 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 8.01: Other Events

  • Genomics sale to Zoetis remains pending, subject to regulatory approvals and customary closing conditions
  • ACCC and NZCC reviews continue, extending expected regulatory clearance to early 2027
Filed Oct 26, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Shareholders approved the amended and restated 2023 Omnibus Incentive Plan on October 1, 2026
  • Plan authorizes equity awards for employees, executives, subsidiaries’ employees and non-employee directors
Filed Oct 7, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • 176,180,487 of 218,106,005 eligible shares voted, indicating approximately 80.8% participation
  • All three director nominees elected, with strongest support for Raphael A. Rodriguez and Catherine E. Woteki

AI summaries of NEOG 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for NEOG

Don't miss the next NEOG filing

  • Alerts as it files. A push when NEOG files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut NEOG, by share count.
  • Ask anything. An AI agent that reads every NEOG filing and answers with sources.

NEOG alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Yarwood JeremySellNov 4, 2026$12.67
Yarwood JeremyMNov 3, 2026$11.82
Yarwood JeremyFNov 3, 2026$11.82
Freels Joe BANov 2, 2026-
Freels Joe BANov 2, 2026$11.82
Green Ronald DMOct 29, 2026$12.21
Green Ronald DMOct 29, 2026$12.21
CAPELLO JEFFREY DMOct 29, 2026$12.21

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2024FY2025FY2026
Profitability
Revenue-$894.7M$870.4M
Gross Profit-$421.4M$408.5M
Operating Income--$1.1B-$21.6M
Net Income-$9.4M-$1.1B-$7.9M
Gross Margin-47.1%46.9%
Op. Margin--118.6%-2.5%
Net Margin--122.1%-0.9%
Balance Sheet
Total Assets-$3.4B$3.3B
Equity$3.1B$2.1B$2.1B
ROE-0.3%-52.7%-0.4%
Per Share
EPS$-0.04$-5.03$-0.04
Cash Flow
Operating CF$35.3M$58.2M$83.2M

Source: XBRL data in NEOGEN CORP (NEOG)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate NEOG share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
NEOG shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202632$1.21B
Q2 202630$869.5M
Q1 202628$903.7M
Q4 202528$689.5M
Q3 202528$594.7M
Q2 202529$485.8M
Q1 202526$562.4M
Q4 202423$574.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 224 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

NEOG filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 4, 2026--
8-KNov 4, 2026Analysis-
4Nov 3, 2026--
4Oct 30, 2026--
4Oct 30, 2026--
4Oct 30, 2026--
4Oct 30, 2026--
4Oct 30, 2026--
4Oct 30, 2026--
4Oct 30, 2026--
8-KOct 26, 2026Analysis-
4Oct 23, 2026--
4Oct 9, 2026--
8-KOct 7, 2026Analysis-
10-QOct 7, 2026Analysis
8-KOct 6, 2026Analysis-
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Aug 20, 2026--

Related Health Care companies

All Health Care →

NEOG SEC filings: frequently asked questions

Are NEOG insiders buying or selling?

In the last 90 days, NEOGEN CORP (NEOG) officers, directors and 10% owners reported 1 open-market purchase worth $6,035 by 1 insider and 1 open-market sale worth $114,676 by 1 insider on Form 4, a net sale of $108,641. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold NEOG stock?

As of September 30, 2026, the largest NEOGEN CORP (NEOG) holders among the 13F filers tracked by SignalX were BlackRock ($422.1 million), Vanguard Portfolio Management LLC ($166.0 million), Dimensional Fund Advisors ($131.6 million), Vanguard Capital Management LLC ($123.8 million), State Street Corp ($114.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was NEOG's revenue in fiscal year 2026?

For the fiscal year ended May 31, 2026 (FY2026), NEOGEN CORP (NEOG) reported revenue of $870.4 million (down 2.7% from FY2025) and a net loss of $7.9 million. Diluted EPS was -$0.04. The figures come from the XBRL data in the 10-K.

What are the main risks in NEOG's latest 10-K?

In the 10-K filed July 30, 2026, NEOGEN CORP (NEOG) flagged: Regulatory risk from Australian and New Zealand regulators reviewing $160M Genomics business sale to Zoetis, delaying expected closing beyond H1 FY2027. Geopolitical exposure with 51.2% revenue from international markets facing risks including Russia-Ukraine conflict sanctions and Middle East tensions impacting supply and costs. (AI summary of the Risk Factors section.)

What did NEOG report in its latest 8-K?

NEOGEN CORP (NEOG) filed an 8-K on November 4, 2026 reporting Item 8.01 (Other Events). Genomics sale to Zoetis remains pending, subject to regulatory approvals and customary closing conditions.

What are the latest NEOG SEC filings?

NEOGEN CORP (NEOG) filed its latest 10-K annual report on July 30, 2026, a 10-Q quarterly report on October 7, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 4, 2026.

What is NEOG's SEC CIK number?

NEOGEN CORP (NEOG)'s SEC Central Index Key (CIK) is 711377. EDGAR lists every NEOG filing under that number.

Ask anything about NEOG

The research agent reads NEOG's filings, financials, insider trades and 13F holders, then answers with sources.